UNSPSC 51142571: Rotigotine hydrochloride

This classification denotes a dopamine agonist with the molecular formula C19H25NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q1W9573L2, chemically known as rotigotine hydrochloride, (-)-, but more generally known as rotigotine hydrochloride, which bears US NIH Compound Identifier 180335. European Medicines Agency schedules rotigotine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21254.

Most nations, for tariff purposes, schedule rotigotine hydrochloride under HS 29349990. SMILES: CCCN(CCC1CCCS1)[C@H]2CCC3C(CCCC3O)C2.CL.

UNSPSC 51142571 Rotigotine hydrochloride is a Commodity code that nominally encompasses a specific pharmaceutical active ingredient, but the recent state and local procurement activity under this code shows a substantial mismatch: the sole recent opportunity tagged to this code is Seminole County, Florida's IFB for naloxone and drug deactivation systems, which bears no direct relationship to rotigotine hydrochloride (a dopamine agonist used for Parkinson's disease and restless leg syndrome). The tagging appears to be a data error or miscategorization in the procurement system rather than a reflection of actual purchasing patterns under this code. State and local governments procuring pharmaceutical products typically solicit through agencies handling public health, emergency medical services, or community health initiatives, as illustrated by Seminole County's approach through its Community Health Building.

The geographic activity is limited to Florida based on available records. Seminole County's IFB (IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, represents the only recent opportunity in the dataset. The procurement sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bidders required to submit electronic bids including all shipping and delivery costs. The contract included a two-year initial term with a one-year renewal option, E-Verify compliance, drug-free workplace certification, and standard insurance requirements. Given the code's mismatch with the actual solicitation content and the absence of other recent rotigotine-specific opportunities, this code shows little relevant activity for vendors in the pharmaceutical supply chain.